CARGO Therapeutics Inc. C...

4.66
0.02 (0.43%)
At close: Apr 17, 2025, 3:59 PM
4.64
-0.32%
After-hours: Apr 17, 2025, 04:05 PM EDT
0.43%
Bid 4.61
Market Cap 214.37M
Revenue (ttm) n/a
Net Income (ttm) -167.5M
EPS (ttm) -3.74
PE Ratio (ttm) -1.24
Forward PE -1.81
Analyst Hold
Ask 4.69
Volume 397,689
Avg. Volume (20D) 1,194,380
Open 4.60
Previous Close 4.64
Day's Range 4.54 - 4.72
52-Week Range 3.00 - 25.45
Beta 0.64

About CRGX

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cell...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 13, 2023
Employees 167
Stock Exchange NASDAQ
Ticker Symbol CRGX
Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for CRGX stock is "Hold." The 12-month stock price forecast is $4, which is a decrease of -14.07% from the latest price.

Stock Forecasts
4 weeks ago
+9.21%
CARGO Therapeutics shares are trading higher after... Unlock content with Pro Subscription
2 months ago
-74.3%
Cargo Therapeutics shares are trading lower after five firms downgraded the stock and Jefferies cut its price target from $32 to $3.